Navigation Links
Concurrent chemo and radiation confers survival benefit in nasopharyngeal carcinoma patients
Date:11/4/2011

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

Nasopharyngeal carcinoma is endemic in Southern China and Southeast Asia, where radiotherapy (RT) has been the primary treatment. Although the National Comprehensive Cancer Network (NCCN) recommends concurrent chemo-radiotherapy (CCRT) for stage II disease, evidence regarding its efficacy is weak, and this has not been defined as a primary endpoint in phase III trials.

To determine whether or not combined chemotherapy and radiotherapy confers survival benefit to stage II NPC patients, Qui-Yan Chen, M.D., Ph.D., of the Sun Yat-sen University Cancer Center in the People's Republic of China, and colleagues, conducted a phase III trial of patients randomly assigned to receive either radiation therapy (114 patients) or combined chemotherapy and radiation (116 patients).

They also found that after a median follow-up of 60 months, 22.8% of patients in the radiation group had disease progression, compared to 11.2% in the concurrent therapy group. The researchers found that 5-year overall survival, progression-free survival, and distant metastasis-free survival were statistically significantly higher in the concurrent therapy group compared with the group receiving radiation alone.

The authors conclude that based on the results of this trial, which they believe to be the first phase III trial to compare CCRT and RT, the NCCN guidelines are reasonable. They hypothesize that early-stage disease may have a smaller distant tumor bulk, and thus CCRT may be more effective in eradicating distant micro-metastases. Although patients in the combined therapy group experienced more toxic side effects than patients who only received radiotherapy, the regimen was overall well tolerated whe
'/>"/>

Contact: Kristine Crane
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. New study introduces the prospect for concurrent antiangiogenic/antitumorigenic therapy
2. Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer
3. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. Scientists identify microRNA as possible cause of chemotherapy resistance
6. Study evaluates costs and benefits of new chemotherapy drugs
7. Older Colon Cancer Patients Less Likely to Get Chemo
8. Are New Chemo Treatments Cost-Effective?
9. BioSphere Medical's HepaSphere Microspheres Safely Deliver Doxorubicin in Liver Cancer Chemoembolization Therapy -- Study Presented at SIR
10. Researchers find new chemotherapy combination shows promise in endometrial cancer
11. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 4 pm EDT): In a Viewpoint published today ... , a team of Boston researchers call for the ... in the United States. The researchers from the Friedman ... Harvard University and Boston Children,s Hospital write that policies ... could both help people make meaningful dietary changes and ...
(Date:9/2/2014)... Friendship Village of Schaumburg is proud to ... contemporary marketing presence and visually solidifies the relationship ... Senior Options,” said Stephen A. Yenchek, president and ... logo, we are making sure that our identity ... families.” , Friendship Village is a retirement community ...
(Date:9/2/2014)... Los Angeles, CA (PRWEB) September 02, 2014 ... an article on its website titled “Why You Should ... more than 80 percent of the global population breathes ... droplets and particles of pollution lodge in the skin’s ... the body’s natural barrier to free radicals that may ...
(Date:9/2/2014)... 2014 In a large population-based study of ... mild cognitive impairment (MCI) occurred twice more often ... Interestingly, this strong association was only observed in ... (66-80 years) the association vanished. This study is ... . , The concept of MCI describes an ...
(Date:9/2/2014)... 02, 2014 The Dream2Walk Foundation along with ... Sept. 14th, 2014 during Spinal Cord Injury Awareness Month featuring ... England, and Chuck Ligon. Linear Automotive will be there hosting ... , Doors open at 2pm. The car show is Pre ... free pass to the concert. There will be trophies for ...
Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2
... Releases First-year Results of Guiding Stars, ... Rating System, SCARBOROUGH, Maine, Sept. 6 Consumer,selection ... are outpacing,selection of those that don,t in many aisles ... times faster -- according to data in the year,since ...
... a proven treatment -, BELLEVILLE, ON, Sept. ... a research-based, technology-driven Canadian,biopharmaceutical company, today announced that ... in order to be able to respond to ... equine influenza outbreak.,The outbreak began in August, and ...
... MYL ) today announced that Mylan Pharmaceuticals Inc. has ... for its,Abbreviated New Drug Application (ANDA) for Carvedilol Tablets, ... Carvedilol Tablets are the generic version of GlaxoSmithKline,s,Coreg(R) Tablets. ... the 12 months ending June 30, 2007, for the ...
... Mich. More than 10 percent of women with ... of joint and muscle pain, according to a new ... Cancer Center. , The women in the study were ... block the production of estrogen, which fuels some breast ...
... a national,ground beef producer, is voluntarily recalling from ... ground beef patties, sold fresh,under the Shaw,s label, ... on Wednesday September 5, 2007 approximately between 7am ... product has been removed from saledue,to concerns about ...
... Ventas, Inc. (NYSE:,VTR) ("Ventas" or the "Company") said ... dividend of $0.475 per share, payable in cash,on September ... 2007. The,dividend is the third quarterly installment of the ... is a leading healthcare real estate investment trust. Its,diverse ...
Cached Medicine News:Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 2Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 3Health News:Grocery Shoppers Are Following Stars to More Nutritious Choices 4Health News:Bioniche Responds to Australian Equine Influenza Outbreak 2Health News:Bioniche Responds to Australian Equine Influenza Outbreak 3Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 2Health News:13 percent of women stop taking breast cancer drug because of side effects, U-M study finds 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.475 Per Share 4
(Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... , HAMBURG , Feb. 3 ... Wound Therapy (NPWT) will assemble this week to develop a ... NPWT Expert Panel is drafting recommendations for a range of ... published clinical evidence.  Where published evidence is insufficient, the Panel ...
... Feb. 2 Celsis In Vitro, Inc. (Celsis IVT) ... XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. ... Illinois in Chicago .  XenoTech and Sekisui Medical ... processes and methods performed by XenoTech associated with its in ...
Cached Medicine Technology:International NPWT Expert Panel Convenes in Hamburg 2International NPWT Expert Panel Convenes in Hamburg 3Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
... Designed for the Anterior Segment The ... lens practitioners and ophthalmologists specializing in the anterior ... emergency rooms. Video- c-mount camera on the BD ... port. Standard magnification in 10 and 16 X ...
... FVL is a new functional test which ... Activated Protein C Resistance caused by the ... to other commercially available methods, Pefakit APC-R ... or S, Lupus Anticoagulants, Elevated FVIII levels, ...
... Used for venous pressure monitoring, blood ... fluids. Turbo-Flo polyurethane PICC line sets ... Rates, Micropuncture Introducer Needle, ... be trimmed to patient specific anatomy. ...
Assess serum Gc-globulin levels in patients with multiple trauma, fulminant liver failure, acetaminophen overdose, and sepsis....
Medicine Products: